Loading...
Guest User
Welcome! Please login.
| IPO Listing At | NSE SME |
| SME IPO Issue Type | Book Build Issue |
| Total Issue Size | ₹29.34 Cr |
| Reserved for Market Maker | ₹0.00 Cr |
| Net Issue Size | ₹29.34 Cr |
| Fresh Issue | ₹27.85 Cr |
| Face Value | ₹10 Per Equity Share |
| Price Band | ₹58.00-61.00 per share |
| Discount | Retail: 0.00 |
| NSE Code | ONYX |
| Registrar | MAS Services Ltd. |
| Lead Managers | Horizon Management Pvt.Ltd. |
Disclaimer: GMP is sourced from grey market dealers and is indicative only. Always conduct your own due diligence.
* Allotment, Refund, Demat Credit & Listing dates are tentative and subject to change.
Minimum bid: 2,000 shares and in multiples thereof
Incorporated in May 2005, Onyx Biotec Limited is a pharmaceutical company providing sterile water for injections. The company currently manufactures Sterile Water for Injections and serves as a pharmaceutical contract manufacturer, offering a comprehensive range of Dry Powder Injections and Dry Syrups for both the Indian and overseas markets.
The company has two manufacturing units in Solan, Himachal Pradesh. Unit I has a daily production capacity of 638,889 units of Sterile Water for Injections, while Unit II produces 40,000 units of dry powder injections and 26,667 units of dry syrup per day in a single shift.
The company clientele includes Hetero Healthcare Limited, Mankind Pharma Limited, Sun Pharmaceutical Industries Limited, Aristo Pharmaceuticals Private Limited, Macleods Pharmaceuticals Limited, Mapra Laboratories Private Limited, Axa Parenterals Limited, FDC Limited, Zuventus Healthcare Limited, Akums Drugs and Pharmaceuticals Limited, Reliance Life Sciences Limited, among others.
As of May 31, 2024, the company had a client base of more than 100 Indian and multinational pharmaceutical companies.
The company has received certificates for the management system, ISO 9001:2015, and ISO 14001:2015 from ROHS Certification Private Limited.
As of July 31, 2024, the company has 175 employees across various departments.
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Upgradation of existing manufacturing Unit I to manufacture large volume parentals for intravenous use; | 6.08 |
| 2 | Setting up a high-speed cartooning packaging line at existing manufacturing Unit II for Dry Powder Injections; | 1.24 |
| 3 | Prepayment or repayment of all or a portion of certain loans availed by the Company; and | 12.00 |
| 4 | General Corporate Purposes | 6.00 |
| Period Ended | 31 May 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|---|
| Assets | 74.77 | 74.14 | 58.72 | 36.84 |
| Total Income | 10.54 | 53.87 | 39.62 | 44.98 |
| Profit After Tax | 1.31 | 3.03 | 1.84 | 3.35 |
| NET Worth | 26.19 | 24.88 | 18.20 | 16.38 |
| Reserves and Surplus | 12.86 | 11.56 | 12.30 | 10.47 |
| Total Borrowing | 31.56 | 30.78 | 29.23 | 12.24 |
| Amount in ₹ Crore | ||||
| KPI | May 31, 2024 |
|---|---|
| ROE | 4.99% |
| ROCE | 3.71% |
| Debt / Equity | 1.21% |
| RoNW | 4.99% |
| PAT Margin | 12.42% |
| Price to Book Value | 3.10 |
| Metric | Pre IPO | Post IPO |
|---|---|---|
| EPS (₹) | 2.28 | 4.33 |
| P/E (x) | 26.81 | 14.1 |
| Promoter Holding | 88.6% | 65.1% |
| Market Cap | ₹110.61 Cr. | |
